BlackRock, Inc. filed Amendment No. 3 to Schedule 13G with the SEC on October 27, 2026, disclosing beneficial ownership of 2,851,023 shares of RxSight, Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock reported beneficially owning 2,851,023 shares of RxSight, Inc. common stock.
  • Percent of class: The reported stake represents 6.9% of the outstanding common shares.
  • Sole voting power: BlackRock disclosed sole voting power over 2,782,168 shares.
  • Sole dispositive power: BlackRock disclosed sole dispositive power over 2,851,023 shares.
  • Shared voting and dispositive power: Both shared voting power and shared dispositive power are reported as 0.
  • Event date: The date of the event requiring this filing is September 30, 2026.
  • Certification: The filing was signed by Spencer Fleming, Managing Director of BlackRock, Inc., dated October 27, 2026.

BlackRock's Amended Beneficial Ownership Position in RxSight

According to the filing, BlackRock, Inc., organized in Delaware and headquartered at 50 Hudson Yards, New York, NY 10001, submitted Amendment No. 3 to Schedule 13G disclosing its beneficial ownership in RxSight, Inc. (issuer address: 100 Columbia Street, Suite 120, Aliso Viejo, CA 92656). The filing covers RxSight common stock with CUSIP number 78349D107. BlackRock is identified as a parent holding company (type "HC") and the disclosure is made under Rule 13d-1(b).

The filing states that the Schedule 13G "reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates," and that it does not include securities beneficially owned by other business units whose beneficial ownership is disaggregated in accordance with SEC Release No. 34-39538. The identities of the relevant subsidiaries are provided in Exhibit 99 to the filing.

Regarding Item 6, the filing discloses that "various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of RxSight, Inc." and confirms that no single person's interest in the common stock exceeds 5% of the total outstanding common shares. BlackRock certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of RxSight.

What Was Disclosed

BlackRock, Inc. filed Amendment No. 3 to Schedule 13G reporting beneficial ownership of 2,851,023 shares, or 6.9%, of RxSight, Inc. common stock as of September 30, 2026, with sole voting power over 2,782,168 shares and sole dispositive power over all 2,851,023 shares.